Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Camurus AB ( (SE:CAMX) ).
Camurus highlights its mission to address significant unmet medical needs in conditions like opioid dependence, acromegaly, and neuroendocrine tumors through long-acting therapies based on its FluidCrystal technology. The company positions these science-driven innovations as a way to enhance treatment outcomes, reduce disease burden, and deliver broader benefits for patients and society, underscoring its strategic focus on transforming care for severe and chronic illnesses.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK700.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
More about Camurus AB
Camurus AB is a pharmaceutical company focused on developing innovative, long-acting medicines for severe and chronic diseases. Leveraging its proprietary FluidCrystal technology, the company targets conditions such as opioid dependence, acromegaly, and neuroendocrine tumors, aiming to improve treatment outcomes and quality of life for patients worldwide.
Average Trading Volume: 133,137
Technical Sentiment Signal: Hold
Current Market Cap: SEK32.24B
Find detailed analytics on CAMX stock on TipRanks’ Stock Analysis page.